Allos Therapeutics Appoints Pablo J. Cagnoni, M.D. as Chief Medical Officer
20 3월 2007 - 9:00PM
PR Newswire (US)
WESTMINSTER, Colo., March 20 /PRNewswire-FirstCall/ -- Allos
Therapeutics, Inc. (NASDAQ:ALTH) today announced the appointment of
Pablo J. Cagnoni, M.D. as Senior Vice President, Chief Medical
Officer. In this position, Dr. Cagnoni will lead the company's
clinical development functions, including clinical operations,
medical affairs and biometrics. "We are delighted to welcome Pablo
to Allos," said Paul L. Berns, President and CEO. "Pablo's
extensive oncology drug development experience and demonstrated
track record of building clinical development organizations will be
extremely valuable as we look to advance our product candidates,
seek new drugs for development and continue to work to deliver
promising new therapies to cancer patients." Dr. Cagnoni brings to
Allos nearly twenty years of drug development experience in
oncology in both industry and academia. From 2004 to 2007, Dr.
Cagnoni held several key management positions with OSI
Pharmaceuticals, Inc., serving most recently as Chief Medical
Officer and Vice President, Clinical Research and Medical Affairs.
During his tenure at OSI, among other responsibilities, Dr. Cagnoni
oversaw all of the company's clinical development and medical
affairs activities relating to Tarceva(R). From 2001 to 2004, Dr.
Cagnoni held key roles in clinical development with Allos, serving
most recently as Vice President, Clinical Development. Prior to
that, Dr. Cagnoni was Assistant Professor of Medicine in the
Division of Oncology at the University of Colorado, where he also
served as Assistant Director of the Pharmacology Laboratory and
member of the Bone Marrow Transplant Program. Dr. Cagnoni graduated
Summa Cum Laude from the University of Buenos Aires Medical School
and received training in Hematology and Oncology at Mount Sinai
Medical Center in New York and in Bone Marrow Transplantation at
the University of Colorado. Dr. Cagnoni has authored over 50
publications, numerous book chapters and has lectured extensively
in several areas related to clinical oncology and drug development.
"I am thrilled to accept this position and return to Allos to lead
the company's research and development activities," said Dr.
Cagnoni. "I believe Allos has a promising pipeline of product
candidates that have the potential to address areas of significant
unmet medical need." About Allos Therapeutics, Inc. Allos
Therapeutics, Inc. (ALTH) is a biopharmaceutical company focused on
the development and commercialization of small molecule
therapeutics for the treatment of cancer. The Company has two
product candidates in late-stage clinical development: EFAPROXYN
(efaproxiral), a radiation sensitizer currently under evaluation in
a pivotal Phase 3 trial in women with brain metastases originating
from breast cancer, and PDX (pralatrexate), a novel, next
generation antifolate currently under evaluation in a pivotal Phase
2 trial in patients with relapsed or refractory peripheral T-cell
lymphoma. The Company is also evaluating RH1, a targeted
chemotherapeutic agent, in a Phase 1 trial in patients with
advanced solid tumors. For additional information, please visit the
Company's website at http://www.allos.com/. NASDAQ Notice In
connection with the commencement of Dr. Cagnoni's employment, on
March 19, 2007, the Company granted Dr. Cagnoni 75,000 shares of
restricted stock and options to purchase 300,000 shares of common
stock under the Company's 2006 Inducement Award Plan. Dr. Cagnoni's
restricted stock vests over a four-year period, with 25% of the
restricted stock vesting on each of the first four anniversaries of
the date of grant. Dr. Cagnoni's options have an exercise price of
$6.17 per share, which equals the closing sale price of a share of
the Company's common stock on the date of grant, and are
non-qualified options for tax purposes. The options have a ten year
term, and vest over a four year period, with 25% of such options
vesting one year after the date of grant, and the remaining 75% of
such options vesting in equal monthly installments thereafter over
the next three years. Any unvested portions of the restricted stock
and options will be forfeited upon the termination of Dr. Cagnoni's
employment with the Company, except if the Company (or any
surviving or acquiring corporation) terminates Dr. Cagnoni's
employment without cause or if he resigns for good reason within
one month prior to or thirteen months following a change in control
of the Company, in which case the restricted stock and options will
vest in full. The restricted stock and options were approved by the
Compensation Committee of the Company's Board of Directors, and
were granted without stockholder approval pursuant to NASD
Marketplace Rule 4350(i)(1)(A)(iv). Safe Harbor Statement This
press release contains forward-looking statements that are made
pursuant to the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. Such forward-looking statements
include statements relating to Dr. Cagnoni's potential impact on
the future growth and success of the Company; the potential safety,
efficacy and marketability of the Company's product candidates; and
other statements that are other than statements of historical
facts. In some cases, you can identify forward-looking statements
by terminology such as "may," "will," "should," "expects,"
"intends," "plans," "anticipates," "believes," "estimates,"
"predicts," "projects," "potential," "continue," and other similar
terminology or the negative of these terms, but their absence does
not mean that a particular statement is not forward-looking. Such
forward-looking statements are not guarantees of future performance
and are subject to risks and uncertainties that may cause actual
results to differ materially from those anticipated by the
forward-looking statements. These risks and uncertainties include,
among others, that the Company's product candidates are in various
stages of development and may never be fully developed in a manner
suitable for commercialization. If the Company is unable to
develop, receive approval for, or successfully commercialize any of
its product candidates, it will be unable to generate meaningful
revenue from product sales and may never become profitable.
Additional information concerning these and other factors that may
cause actual results to differ materially from those anticipated in
the forward-looking statements is contained in the "Risk Factors"
section of the Company's Annual Report on Form 10-K for the year
ended December 31, 2006 and in the Company's other periodic reports
and filings with the Securities and Exchange Commission. The
Company cautions investors not to place undue reliance on the
forward-looking statements contained in this press release. All
forward-looking statements are based on information currently
available to the Company on the date hereof, and the Company
undertakes no obligation to revise or update these forward-looking
statements to reflect events or circumstances after the date of
this presentation, except as required by law. Note: EFAPROXYN(TM)
and the Allos logo are trademarks of Allos Therapeutics, Inc.
DATASOURCE: Allos Therapeutics, Inc. CONTACT: Jennifer Neiman,
Manager, Corporate Communications of Allos Therapeutics,
+1-720-540-5227, Web site: http://www.allos.com/
Copyright
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024